ASH 2014: Phase III study demonstrates carfilzomib is an effective addition to standard myeloma therapy

ASH 2014: Phase III study demonstrates carfilzomib is an effective addition to standard myeloma therapy

EMJ

5 years
840 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the randomised, open-label, multicentre phase III ASPIRE study. The results of this study suggest carfilzomib combined with standard multiple myeloma therapy (combination of lenalidomide and dexamethasone) improves treatment responses in patients with relapsed or treatment-resistant multiple myeloma.
Up Next Autoplay